Clinical data may determine whether a therapy works. Manufacturing determines whether patients ever receive it.

In this episode of Regulatory: The Emerging C-Suite Leader, hosts Trevor and Debra speak with Edward Kaye, CEO of Aurora Therapeutics, about why Chemistry, Manufacturing and Controls (CMC) is often one of the most consequential, and underestimated, areas of drug development.

For many emerging biotechs, manufacturing receives less attention than clinical strategy until a program reaches a critical milestone. By then, the consequences of weak process controls, incomplete assay development, inadequate oversight, or manufacturing variability can be difficult to unwind. CMC-related issues remain one of the most common causes of regulatory delays and complete response letters.

The challenge is not simply technical. CMC decisions influence regulatory strategy, development timelines, investment planning, commercial readiness, and long-term supply. Success depends on understanding what must be built at each stage of development, and recognizing when future manufacturing risks are being created by decisions made today.

Strong CMC organizations are not built by avoiding difficult conversations. They depend on experienced voices willing to challenge assumptions, raise concerns early, and advocate for investments that may not appear urgent until a problem emerges. The most expensive manufacturing mistake is often the one that could have been prevented years earlier.

Ed repeatedly makes the distinction between avoiding mistakes and learning from them. In CMC, learning from mistakes is often the more expensive option. Many of the issues that delay programs can be traced back to risks that were visible much earlier.

What risks are being created today because manufacturing is not yet part of the strategic conversation? Listen to the full episode with Ed Kaye.

In this episode of Regulatory: The Emerging C-Suite Leader podcast, our hosts Debra Webster and Trevor Mill sit down with Murray Abramson, Chief Development Officer at Ascidian, to explore what it takes to accelerate drug development in complex settings, particularly in diseases with limited patient populations.

Acceleration is often misunderstood. It is not about speed alone. Without a foundation in data, patient insight, and regulatory alignment, timelines are built on hope rather than reality.

The discussion highlights the importance of early, integrated planning across clinical, regulatory, and CMC functions. Misalignment across these areas is one of the most common reasons accelerated programs fall short, particularly when protocols are built in isolation or timelines are set without grounding in prior experience. Adaptive trial designs can create efficiencies, but they are not a universal solution and must be applied in the context of the disease, modality, endpoints, and available biomarkers.

Identifying and continuously reassessing the “source of truth” is critical, meaning grounding decisions in data rather than assumptions. This includes patient needs, enrollment feasibility, regulatory expectations, and operational realities. Successful programs are those that address risks early, create an environment where challenges are surfaced before they become crises, maintain open communication across teams and with regulators, and adapt as new information emerges.

A clear tension exists between urgency and rigor. There is a moral imperative to move quickly for patients, but only when speed is supported by scientific rigor, transparency, and a well-grounded development strategy.

Hear it in Murray's own words.

Investor confidence is built on credible milestones and the ability to deliver on them.

This episode features Rami Rahal, an investor at a leading biotech investment firm with a background spanning genetic research, drug discovery, and successful program development through approval. Having operated on both the development and investment sides, he brings a rare, practical lens on what makes a biotech company fundable.

Key takeaways:

• Milestones define your valuation, and your credibility. They must be grounded in cross-functional alignment and achievable timelines.
• Regulatory leadership is a strategic differentiator. When positioned at the C-suite level, regulatory shapes the development path, anticipates hurdles, and enables efficient, high-quality execution.
• Confidence comes from clarity on risk. Transparent, well-articulated risks, and plans to manage them, build far more trust than over-optimized narratives.
• Execution is what investors underwrite. Enrollment, data generation, and regulatory sequencing are the true drivers of value inflection.
• Experience changes outcomes. Teams that integrate experienced regulatory leadership early are better positioned to deliver on what they promise.
  

For biotech executives, this highlights the importance of elevating regulatory into a core strategic voice strengthens both the development plan and the investor narrative.

Listen to the episode to hear directly from an investor on what builds and breaks confidence.